0000105770false00001057702024-12-092024-12-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – December 9, 2024
wstlogoq319.jpg
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania
1-8036
23-1210010
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
530 Herman O. West Drive, Exton, PA
19341-1147
(Address of principal executive offices)
(Zip Code)
 Registrant’s telephone number, including area code: 610-594-2900
Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 9, 2024, West Pharmaceutical Services, Inc. (the "Company") elected Janet Haugen, to its Board of Directors (the "Board") as its newest member. With the addition of Ms. Haugen, the Board increased in size to 12 directors. Ms. Haugen is expected to participate on the Audit Committee of the Board as of the date of her appointment.

Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Haugen oversaw the company’s business transformation from a mainframe hardware, software and maintenance company to an IT services and software provider. In addition to her core finance responsibilities at the company, she had oversight of Unisys’ corporate development, IT, procurement, facilities and legal functions.

Prior to joining Unisys, Ms. Haugen was a partner at Ernst & Young working with Fortune 500 companies serving global clients in the technology and manufacturing industries.

Ms. Haugen currently serves on the Board of Directors of Bentley Systems, Juniper Networks and CentralSquare Technologies.

Ms. Haugen will be entitled to the customary compensation arrangements for the Company’s non-employee directors, which currently consists of a $100,000 annual retainer and an annual restricted stock unit grant of $220,000. Each element of Ms. Haugen’s compensation will be prorated for her period of service. In addition, she will be eligible to participate in the Company’s Director Deferred Compensation Plan. The Company’s most recent proxy statement, filed with the Securities and Exchange Commission on March 13, 2024, describes these arrangements under the heading “Director Compensation.”

Ms. Haugen will enter into the Company's standard form of indemnification agreement, the form of which was included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on January 6, 2009.

There were no arrangements or understandings between Ms. Haugen and any other person pursuant to which she was elected as a director, and there are and have been no transactions since the beginning of the Company’s last fiscal year, or currently proposed, between the Company and Ms. Haugen.

Item 7.01 Regulation FD Disclosure.

On December 11, 2024, the Company issued a press release announcing the appointment of Ms. Haugen to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit No.
Description
 99.1
West Pharmaceutical Services, Inc. Press Release, dated December 11, 2024
 104
The cover page from the Company’s Current Report on Form 8-K, dated December 9, 2024, formatted in Inline XBRL.



2




SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


WEST PHARMACEUTICAL SERVICES, INC.
/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial Officer
December 11, 2024



3





EXHIBIT INDEX

Exhibit No.
Description
99.1
104
The cover page from the Company’s Current Report on Form 8-K, dated December 9, 2024, formatted in Inline XBRL.

4

wstlogoq319.jpg
Exhibit 99.1

Investor Contact:Media Contact:
John Sweeney, CFAMichele Polinsky
Vice President, Investor RelationsVice President, Global Communications
+1 (484) 790-0373+1 (610) 594-3054
John.Sweeney@westpharma.comMichele.Polinsky@westpharma.com
West Elects New Director to the Board

Exton, Pa., December 11, 2024— West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the Company's Board of Directors has elected Janet Haugen, as its newest member. With the addition of Ms. Haugen, West's Board has 12 directors.

Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Haugen oversaw the business transformation from a mainframe hardware, software and maintenance company to an IT services and software provider. In addition to her core finance responsibilities, she had oversight of Unisys’ corporate development, IT, procurement, facilities and legal functions.

Prior to joining Unisys, Ms. Haugen was a partner at Ernst & Young working with Fortune 500 companies serving global clients in the technology and manufacturing industries.

Ms. Haugen currently serves on the Board of Directors of Bentley Systems, Juniper Networks and CentralSquare Technologies.

Ms. Haugen earned her degree in Economics from Rutgers University. In addition, she is a certified director of the National Association of Corporate Directors (NACD).

“We are pleased to welcome Janet Haugen to West’s Board of Directors,” said Paolo Pucci, Lead Independent Director, West. “Janet’s unique combination of technology and finance expertise makes her an invaluable addition to our Board of Directors. With her significant board experience and proven operational track record, Janet will help us continue to enhance the impact of West’s role to deliver healthcare to millions of patients every day.”


About West

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.    

Headquartered in Exton, Pennsylvania, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

v3.24.3
Cover Page
Dec. 09, 2024
Cover [Abstract]  
Entity Central Index Key 0000105770
Document Type 8-K
Document Period End Date Dec. 09, 2024
Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.
Entity Incorporation, State or Country Code PA
Entity File Number 1-8036
Entity Tax Identification Number 23-1210010
Entity Address, Address Line One 530 Herman O. West Drive
Entity Address, City or Town Exton
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19341-1147
City Area Code 610
Local Phone Number 594-2900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.25 per share
Trading Symbol WST
Security Exchange Name NYSE
Entity Emerging Growth Company false
Amendment Flag false
West Pharmaceutical Serv... (NYSE:WST)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more West Pharmaceutical Serv... Charts.
West Pharmaceutical Serv... (NYSE:WST)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more West Pharmaceutical Serv... Charts.